Cardiovascular Effectiveness of SGLT2i and GLP-1RA vs. Sulfonylureas by Socioeconomic Status—Analysis of U.S. and UK Health Care Systems

Related

• SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes

  Clinical Journal of the American Society of Nephrology · 4 Oct 2026

• Drug class linked to fewer deaths or complications in kidney disease

  The American Journal of Cardiology · 8 Oct 2026

• SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs

  Diabetes & Vascular Disease Research · 4 Oct 2026

• SGLT2 inhibitors raise genital but not urinary infection risk

  Clinical Pharmacology and Therapeutics · 4 Oct 2026